title: [Efficacy studies].
abstract: Pravafenix(®) is a fixed-dose combination of 40mg of pravastatin and 160 mg of fenofibrate. The rationale behind the use of Pravafenix(®) is based on the increased residual cardiovascular risk observed in high risk patients with hypertriglyceridemia and/or low HDL cholesterol levels despite treatment with statins in monotherapy. In this article, we review the available evidence on the clinical efficacy of Pravafenix(®), which shows complementary benefits in the overall lipid profile of high risk patients with mixed dyslipidemia not controlled with 40-mg pravastatin or 20-mg simvastatin.
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España. Electronic address: 86620@parcdesalutmar.cat.
authors.forename: Juan
authors.initials: J
authors.lastname: Pedro-Botet
authors.affiliation: Unidad de Lípidos y Riesgo Vascular, Servicio de Endocrinología y Nutrición, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, España.
authors.forename: Juana A
authors.initials: JA
authors.lastname: Flores-Le Roux
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D008076:Cholesterol, HDL / Q000097:blood; D004338:Drug Combinations; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D011345:Fenofibrate / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D015228:Hypertriglyceridemia / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D017035:Pravastatin / Q000008:administration & dosage / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D008076:Cholesterol, HDL; D004338:Drug Combinations; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D008055:Lipids; D017035:Pravastatin; D011345:Fenofibrate
keywords: Atherogenic dyslipidemia; Clinical efficacy; Colesterol no HDL; Dislipemia aterogénica; Eficacia clínica; Non-HDL cholesterol; Pravafenix(®); Residual cardiovascular risk; Riesgo cardiovascular residual